Related StoriesOvarian tumor patients with a brief history of oral contraceptive use have better outcomesCornell biomedical engineers develop 'very natural killer cells' to destroy cancers cells in lymph nodesNew antenna-like device makes breast cancer surgery less complicated for surgeonsDr. Douglas P. TriPath, a leader in the advancement of molecular diagnostic items for cancer, has in addition undertaken a thorough development system to characterize the optimal mix of molecular biomarkers for the detection of cervical tumor and its own premalignant precursors. These proteins are excellent markers of precancerous and cancerous cells. They allow us to identify abnormalities in cervical smears extremely accurately and can also improve the early medical diagnosis of various other common cancers, for instance those of the huge lung and bowel.?..Bio-Path is currently analyzing Liposomal Grb-2 in a Phase I scientific trial as a systemic treatment for bloodstream cancers including severe myeloid leukemia , chronic myelogenous leukemia , severe lymphoblastic leukemia and myelodysplastic syndrome . The trial has been carried out at The University of Texas MD Anderson Tumor Center . Bio-Path has been around discussions during the last half a year with senior breast tumor experts at the MD Anderson Cancer tumor Middle relating to the potential of its business lead drug applicant Liposomal Grb-2 to take care of TNBC and IBC.